JP2008523825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523825A5 JP2008523825A5 JP2007547125A JP2007547125A JP2008523825A5 JP 2008523825 A5 JP2008523825 A5 JP 2008523825A5 JP 2007547125 A JP2007547125 A JP 2007547125A JP 2007547125 A JP2007547125 A JP 2007547125A JP 2008523825 A5 JP2008523825 A5 JP 2008523825A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- protein
- variant
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 31
- 201000011510 cancer Diseases 0.000 claims 31
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 102000042092 Glucose transporter family Human genes 0.000 claims 13
- 108091052347 Glucose transporter family Proteins 0.000 claims 13
- 102000014914 Carrier Proteins Human genes 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108091008324 binding proteins Proteins 0.000 claims 10
- 229940127121 immunoconjugate Drugs 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims 5
- 239000002619 cytotoxin Substances 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 101710112752 Cytotoxin Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 239000012830 cancer therapeutic Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- -1 bouganin Proteins 0.000 claims 2
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 claims 1
- 108010084592 Saporins Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 108010056243 alanylalanine Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 108010049223 bryodin Proteins 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000012512 characterization method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63744804P | 2004-12-21 | 2004-12-21 | |
| US60/637,448 | 2004-12-21 | ||
| PCT/CA2005/001953 WO2006066408A1 (en) | 2004-12-21 | 2005-12-21 | Cancer specific antibody and cell surface proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012207216A Division JP2013063066A (ja) | 2004-12-21 | 2012-09-20 | 癌特異的抗体および細胞表面タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008523825A JP2008523825A (ja) | 2008-07-10 |
| JP2008523825A5 true JP2008523825A5 (enExample) | 2009-02-05 |
| JP5143566B2 JP5143566B2 (ja) | 2013-02-13 |
Family
ID=36601325
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547125A Expired - Fee Related JP5143566B2 (ja) | 2004-12-21 | 2005-12-21 | 癌特異的抗体および細胞表面タンパク質 |
| JP2012207216A Withdrawn JP2013063066A (ja) | 2004-12-21 | 2012-09-20 | 癌特異的抗体および細胞表面タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012207216A Withdrawn JP2013063066A (ja) | 2004-12-21 | 2012-09-20 | 癌特異的抗体および細胞表面タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8084576B2 (enExample) |
| EP (1) | EP1833968B1 (enExample) |
| JP (2) | JP5143566B2 (enExample) |
| CN (1) | CN101160402B (enExample) |
| AU (1) | AU2005318836B2 (enExample) |
| CA (1) | CA2591768C (enExample) |
| ES (1) | ES2421558T3 (enExample) |
| IL (1) | IL183958A (enExample) |
| NZ (1) | NZ556055A (enExample) |
| RU (1) | RU2007127889A (enExample) |
| WO (1) | WO2006066408A1 (enExample) |
| ZA (1) | ZA200705837B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1737961B1 (en) * | 2004-03-19 | 2013-05-08 | Merck Patent GmbH | Modified bouganin proteins, cytotoxins and methods and uses thereof |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9636329B2 (en) * | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
| CN105764925A (zh) * | 2013-10-02 | 2016-07-13 | 维文蒂亚生物公司 | 抗EpCAM抗体和使用方法 |
| JP6681888B2 (ja) * | 2015-05-29 | 2020-04-15 | 富士フイルム株式会社 | ポリイミド前駆体組成物、感光性樹脂組成物、硬化膜、硬化膜の製造方法、半導体デバイスおよびポリイミド前駆体組成物の製造方法 |
| US10781260B2 (en) | 2016-08-08 | 2020-09-22 | Sorrento Therapeutics, Inc. | Anti-OX40 binding proteins |
| CN108101988B (zh) * | 2016-11-24 | 2021-09-07 | 复旦大学 | 针对cd16的全人源单域抗体、其抗原结合片段及应用 |
| US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
| WO2020086830A2 (en) * | 2018-10-26 | 2020-04-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN114807054B (zh) * | 2022-06-24 | 2022-09-13 | 北京索莱宝科技有限公司 | 小鼠抗人IgG单抗杂交瘤细胞株、抗体、抗体组合物及试剂盒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247538A (en) * | 1982-05-21 | 1988-12-28 | Mark C. Glassy | Human-human hybridomas for solid tumors |
| JPH04346792A (ja) * | 1991-05-22 | 1992-12-02 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列 |
| JPH06141884A (ja) * | 1992-11-06 | 1994-05-24 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列 |
| WO1994016726A1 (en) | 1993-01-22 | 1994-08-04 | Hygeia Pharmaceuticals, Inc. | Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor |
| AU8040898A (en) * | 1997-06-06 | 1998-12-21 | Tanox Pharma B.V. | Type-1 ribosome-inactivating protein |
| US20030228592A1 (en) * | 1997-10-01 | 2003-12-11 | St. Vincent's Institute Of Medical Research | Human facilitative glucose transport protein GLUT8 |
| WO2001004145A2 (en) * | 1999-07-14 | 2001-01-18 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
| US7001735B2 (en) * | 2000-03-01 | 2006-02-21 | Albert Einstein College Of Medicine Of Yeshiva University | Glucose transporter/sensor protein and uses thereof |
| WO2002066516A2 (en) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| ATE483976T1 (de) * | 2001-06-05 | 2010-10-15 | Exelixis Inc | Gfats als modifikatoren des p53-wegs und verwendungsverfahren |
| US20050202559A1 (en) * | 2002-10-29 | 2005-09-15 | Scott Pownall | Cancer treatment by metabolic modulations |
| WO2004095099A1 (en) * | 2003-04-01 | 2004-11-04 | Corning Incorporated | Photonic band gap optical fiber |
-
2005
- 2005-12-21 WO PCT/CA2005/001953 patent/WO2006066408A1/en not_active Ceased
- 2005-12-21 ES ES05823959T patent/ES2421558T3/es not_active Expired - Lifetime
- 2005-12-21 CA CA2591768A patent/CA2591768C/en not_active Expired - Fee Related
- 2005-12-21 EP EP05823959.1A patent/EP1833968B1/en not_active Expired - Lifetime
- 2005-12-21 JP JP2007547125A patent/JP5143566B2/ja not_active Expired - Fee Related
- 2005-12-21 RU RU2007127889/13A patent/RU2007127889A/ru not_active Application Discontinuation
- 2005-12-21 NZ NZ556055A patent/NZ556055A/en not_active IP Right Cessation
- 2005-12-21 AU AU2005318836A patent/AU2005318836B2/en not_active Ceased
- 2005-12-21 CN CN2005800485228A patent/CN101160402B/zh not_active Expired - Fee Related
- 2005-12-21 US US11/722,420 patent/US8084576B2/en active Active
-
2007
- 2007-06-14 IL IL183958A patent/IL183958A/en not_active IP Right Cessation
- 2007-07-16 ZA ZA200705837A patent/ZA200705837B/en unknown
-
2011
- 2011-11-16 US US13/297,783 patent/US8697075B2/en not_active Expired - Lifetime
-
2012
- 2012-09-20 JP JP2012207216A patent/JP2013063066A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102821932B1 (ko) | 항-ccr8 항체 및 이의 용도 | |
| Mao et al. | EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer | |
| JP2008508903A5 (enExample) | ||
| US12037404B2 (en) | Human monoclonal antibodies against EphA4 and their use | |
| JP2011501946A5 (enExample) | ||
| JP2014527398A5 (enExample) | ||
| US8105598B2 (en) | Human monoclonal antibodies that specifically bind IGF-II | |
| US20080260740A1 (en) | Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer | |
| WO2018199318A1 (ja) | 抗ｇｐｃ－１抗体 | |
| JP2014503180A5 (enExample) | ||
| JP2018504112A (ja) | Ｃｘｃｒ４結合分子 | |
| JP2008523825A5 (enExample) | ||
| EP3439700A1 (en) | Biomarkers for anti-leukemic therapy | |
| US20230265208A1 (en) | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | |
| RU2007127889A (ru) | Антитела, специфичные в отношении злокачественной опухоли, и белки клеточной поверхности | |
| JP2024536719A (ja) | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 | |
| KR20230165901A (ko) | Vegfa-결합 분자 | |
| CN108484765B (zh) | 一种抗人α-防御素-1单克隆抗体及其应用 | |
| US7824681B2 (en) | Human monoclonal antibodies that specifically bind IGF-II | |
| US9127056B2 (en) | Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II) | |
| JP2018529716A (ja) | 癌幹細胞を阻害する組成物及び方法 | |
| CN121002061A (zh) | 抗cith3抗体及其用途 | |
| WO2021209017A1 (zh) | 一种特异性结合cd137的制剂及其用途 | |
| HK1235692A1 (en) | Human monoclonal antibodies against epha4 and their use |